Anti-PD1 in the wonder-gut-land

After the initial success of cancer immunotherapy using immune checkpoint blockers, the challenge is to understand why only a minority of patients respond to the therapy and to increase the rate of response. Three recent papers now report that the gut microbiota modulates the response to anti-PD1 th...

Full description

Saved in:
Bibliographic Details
Published in:Cell research 2018-03, Vol.28 (3), p.263-264
Main Authors: Vetizou, Marie, Trinchieri, Giorgio
Format: Article
Language:English
Subjects:
Biomedical and Life Sciences
Cancer
Cancer immunotherapy
Cell Biology
Immune checkpoint
Immune system
Immunotherapy
Intestinal microflora
Life Sciences
Melanoma
Microbiota
Patients
PD-1 protein
Research Highlight
Therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c442t-3098c678731fc2cafa46b2a67a21ea3fdb9c0835e3951320cb1cbbd59ad097913
cites cdi_FETCH-LOGICAL-c442t-3098c678731fc2cafa46b2a67a21ea3fdb9c0835e3951320cb1cbbd59ad097913
container_end_page 264
container_issue 3
container_start_page 263
container_title Cell research
container_volume 28
creator Vetizou, Marie
Trinchieri, Giorgio
description After the initial success of cancer immunotherapy using immune checkpoint blockers, the challenge is to understand why only a minority of patients respond to the therapy and to increase the rate of response. Three recent papers now report that the gut microbiota modulates the response to anti-PD1 therapy in patients with epithelial cancers or melanoma.
doi_str_mv 10.1038/cr.2018.12
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5835771</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1989574876</sourcerecordid><originalsourceid>FETCH-LOGICAL-c442t-3098c678731fc2cafa46b2a67a21ea3fdb9c0835e3951320cb1cbbd59ad097913</originalsourceid><addsrcrecordid>eNptkE1LAzEQhoMoVqsXf4AWvIiyNZNsNslFKPUTCnrQc8hms-2WNluTXcV_b0pr_cDTDMzDOzMPQkeA-4CpuDS-TzCIPpAttAc8FQkXVGzHHmNIcIZJB-2HMMWYsJTBLuoQSWmWUthDJwPXVMnTNfQq12smtvdeu8L6ZNw2yUy74gDtlHoW7OG6dtHL7c3z8D4ZPd49DAejxKQpaRKKpTAZF5xCaYjRpU6znOiMawJW07LIpcGCMkslA0qwycHkecGkLrDkEmgXXa1yF20-t4WxrvF6pha-mmv_oWpdqd8TV03UuH5TLKZyvgw4Wwf4-rW1oVHzKhg7i0_Yug0KpJAsuuFZRE__oNO69S6-pwjGkglg0WsXna8o4-sQvC03xwBWS-_KeLX0roBE-Pjn-Rv0S3QELlZAiCM3tv575z9xn-7YiZI</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2009581510</pqid></control><display><type>article</type><title>Anti-PD1 in the wonder-gut-land</title><source>NCBI_PubMed Central（免费）</source><source>Springer Link</source><creator>Vetizou, Marie ; Trinchieri, Giorgio</creator><creatorcontrib>Vetizou, Marie ; Trinchieri, Giorgio</creatorcontrib><description>After the initial success of cancer immunotherapy using immune checkpoint blockers, the challenge is to understand why only a minority of patients respond to the therapy and to increase the rate of response. Three recent papers now report that the gut microbiota modulates the response to anti-PD1 therapy in patients with epithelial cancers or melanoma.</description><identifier>ISSN: 1001-0602</identifier><identifier>EISSN: 1748-7838</identifier><identifier>DOI: 10.1038/cr.2018.12</identifier><identifier>PMID: 29336431</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>Biomedical and Life Sciences ; Cancer ; Cancer immunotherapy ; Cell Biology ; Immune checkpoint ; Immune system ; Immunotherapy ; Intestinal microflora ; Life Sciences ; Melanoma ; Microbiota ; Patients ; PD-1 protein ; Research Highlight ; Therapy</subject><ispartof>Cell research, 2018-03, Vol.28 (3), p.263-264</ispartof><rights>Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences 2018</rights><rights>Copyright Nature Publishing Group Mar 2018</rights><rights>Copyright © 2018 Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences 2018 Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c442t-3098c678731fc2cafa46b2a67a21ea3fdb9c0835e3951320cb1cbbd59ad097913</citedby><cites>FETCH-LOGICAL-c442t-3098c678731fc2cafa46b2a67a21ea3fdb9c0835e3951320cb1cbbd59ad097913</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5835771/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5835771/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29336431$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Vetizou, Marie</creatorcontrib><creatorcontrib>Trinchieri, Giorgio</creatorcontrib><title>Anti-PD1 in the wonder-gut-land</title><title>Cell research</title><addtitle>Cell Res</addtitle><addtitle>Cell Res</addtitle><description>After the initial success of cancer immunotherapy using immune checkpoint blockers, the challenge is to understand why only a minority of patients respond to the therapy and to increase the rate of response. Three recent papers now report that the gut microbiota modulates the response to anti-PD1 therapy in patients with epithelial cancers or melanoma.</description><subject>Biomedical and Life Sciences</subject><subject>Cancer</subject><subject>Cancer immunotherapy</subject><subject>Cell Biology</subject><subject>Immune checkpoint</subject><subject>Immune system</subject><subject>Immunotherapy</subject><subject>Intestinal microflora</subject><subject>Life Sciences</subject><subject>Melanoma</subject><subject>Microbiota</subject><subject>Patients</subject><subject>PD-1 protein</subject><subject>Research Highlight</subject><subject>Therapy</subject><issn>1001-0602</issn><issn>1748-7838</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNptkE1LAzEQhoMoVqsXf4AWvIiyNZNsNslFKPUTCnrQc8hms-2WNluTXcV_b0pr_cDTDMzDOzMPQkeA-4CpuDS-TzCIPpAttAc8FQkXVGzHHmNIcIZJB-2HMMWYsJTBLuoQSWmWUthDJwPXVMnTNfQq12smtvdeu8L6ZNw2yUy74gDtlHoW7OG6dtHL7c3z8D4ZPd49DAejxKQpaRKKpTAZF5xCaYjRpU6znOiMawJW07LIpcGCMkslA0qwycHkecGkLrDkEmgXXa1yF20-t4WxrvF6pha-mmv_oWpdqd8TV03UuH5TLKZyvgw4Wwf4-rW1oVHzKhg7i0_Yug0KpJAsuuFZRE__oNO69S6-pwjGkglg0WsXna8o4-sQvC03xwBWS-_KeLX0roBE-Pjn-Rv0S3QELlZAiCM3tv575z9xn-7YiZI</recordid><startdate>20180301</startdate><enddate>20180301</enddate><creator>Vetizou, Marie</creator><creator>Trinchieri, Giorgio</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7QP</scope><scope>7QR</scope><scope>7T5</scope><scope>7TK</scope><scope>7TM</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20180301</creationdate><title>Anti-PD1 in the wonder-gut-land</title><author>Vetizou, Marie ; Trinchieri, Giorgio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c442t-3098c678731fc2cafa46b2a67a21ea3fdb9c0835e3951320cb1cbbd59ad097913</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Biomedical and Life Sciences</topic><topic>Cancer</topic><topic>Cancer immunotherapy</topic><topic>Cell Biology</topic><topic>Immune checkpoint</topic><topic>Immune system</topic><topic>Immunotherapy</topic><topic>Intestinal microflora</topic><topic>Life Sciences</topic><topic>Melanoma</topic><topic>Microbiota</topic><topic>Patients</topic><topic>PD-1 protein</topic><topic>Research Highlight</topic><topic>Therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vetizou, Marie</creatorcontrib><creatorcontrib>Trinchieri, Giorgio</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>ProQuest_Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>ProQuest Biological Science Journals</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cell research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vetizou, Marie</au><au>Trinchieri, Giorgio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Anti-PD1 in the wonder-gut-land</atitle><jtitle>Cell research</jtitle><stitle>Cell Res</stitle><addtitle>Cell Res</addtitle><date>2018-03-01</date><risdate>2018</risdate><volume>28</volume><issue>3</issue><spage>263</spage><epage>264</epage><pages>263-264</pages><issn>1001-0602</issn><eissn>1748-7838</eissn><abstract>After the initial success of cancer immunotherapy using immune checkpoint blockers, the challenge is to understand why only a minority of patients respond to the therapy and to increase the rate of response. Three recent papers now report that the gut microbiota modulates the response to anti-PD1 therapy in patients with epithelial cancers or melanoma.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>29336431</pmid><doi>10.1038/cr.2018.12</doi><tpages>2</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1001-0602
ispartof Cell research, 2018-03, Vol.28 (3), p.263-264
issn 1001-0602
1748-7838
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5835771
source NCBI_PubMed Central（免费）; Springer Link
subjects Biomedical and Life Sciences
Cancer
Cancer immunotherapy
Cell Biology
Immune checkpoint
Immune system
Immunotherapy
Intestinal microflora
Life Sciences
Melanoma
Microbiota
Patients
PD-1 protein
Research Highlight
Therapy
title Anti-PD1 in the wonder-gut-land
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T12%3A19%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Anti-PD1%20in%20the%20wonder-gut-land&rft.jtitle=Cell%20research&rft.au=Vetizou,%20Marie&rft.date=2018-03-01&rft.volume=28&rft.issue=3&rft.spage=263&rft.epage=264&rft.pages=263-264&rft.issn=1001-0602&rft.eissn=1748-7838&rft_id=info:doi/10.1038/cr.2018.12&rft_dat=%3Cproquest_pubme%3E1989574876%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c442t-3098c678731fc2cafa46b2a67a21ea3fdb9c0835e3951320cb1cbbd59ad097913%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2009581510&rft_id=info:pmid/29336431&rfr_iscdi=true